Creutzfeldt-Jakob disease in recipients of human growth hormone in the United Kingdom: a clinical and radiographic study.
In the past 3 years there have been five further cases, in addition to one case reported in 1985, of Creutzfeldt-Jakob disease in recipients of human growth hormone in the United Kingdom. The clinical findings of two of these cases are described, demonstrating a typical presentation with a predominantly cerebellar syndrome at onset which is not commonly a presenting feature of sporadic Creutzfeldt-Jakob disease. In one case a 99mTc hexamethylpropylenamine single photon emission tomographic scan showed marked impairment of tracer uptake in the basal ganglia and cerebral cortex at a time when the clinical picture was predominantly cerebellar. This technique may be useful in early diagnosis. In the other case post mortem examination of the brain showed prominent amyloid deposition in the cerebellum, which has not been described previously in pituitary-hormone related Creutzfeldt-Jakob disease. The previously published cases of growth hormone-related Creutzfeldt-Jakob disease are reviewed and reasons for the particular clinical pattern seen are discussed.
Markus
H S
HS
Department of Neurology, Middlesex Hospital, London.
Duchen
L W
LW
Parkin
E M
EM
Kurtz
A B
AB
Jacobs
H S
HS
Costa
D C
DC
Harrison
M J
MJ
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging; D002531:Cerebellum / Q000473:pathology; D007562:Creutzfeldt-Jakob Syndrome / Q000000981:diagnostic imaging / Q000473:pathology / Q000635:transmission*; D004340:Drug Contamination; D013006:Growth Hormone; D006801:Humans; D008297:Male; D013788:Thalamus / Q000473:pathology; D015899:Tomography, Emission-Computed, Single-Photon
D013006:Growth Hormone